Profile data is unavailable for this security.
About the company
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics to overcome the limitations of anticoagulation therapy. It has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
- Revenue in USD (TTM)0.00
- Net income in USD-14.39m
- Incorporated2022
- Employees4.00
- LocationCadrenal Therapeutics Inc822 A1a North, Suite 306PONTE VEDRA 32082United StatesUSA
- Phone+1 (904) 300-0701
- Fax+1 (302) 655-5049
- Websitehttps://www.cadrenal.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moleculin Biotech Inc | 0.00 | -41.36m | 11.69m | 17.00 | -- | -- | -- | -- | -55.88 | -55.88 | 0.00 | -13.60 | 0.00 | -- | -- | 0.00 | -189.07 | -49.52 | -254.72 | -54.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 26.89 | -- | -24.21 | -- |
| BioCardia Inc | 0.00 | -8.54m | 12.10m | 17.00 | -- | 4.60 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 12.33m | 82.00 | -- | 0.3542 | -- | 1.32 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| GT Biopharma Inc | 0.00 | -9.33m | 12.36m | 1.00 | -- | 0.9355 | -- | -- | -3.38 | -3.38 | 0.00 | 0.4957 | 0.00 | -- | -- | 0.00 | -164.22 | -180.24 | -356.99 | -8,448.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.25 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 12.45m | 1.00 | -- | 1.62 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| TRON Group Inc | 1.01m | -549.47k | 12.51m | 50.00 | -- | -- | -- | 12.39 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| NewcelX AG | 0.00 | -6.21m | 12.63m | 1.00 | -- | 0.4081 | -- | -- | -20.39 | -20.39 | 0.00 | 6.94 | 0.00 | -- | -- | 0.00 | -78.31 | -232.34 | -- | -- | -- | -- | -- | -- | -- | -53.01 | 0.00 | -- | -- | -- | 66.67 | -- | -- | -- |
| OSR Holdings Inc | 2.52m | -15.21m | 12.78m | -- | -- | 0.1433 | -- | 5.06 | -1.73 | -1.73 | 0.1939 | 3.46 | 0.0255 | -- | -- | -- | -22.03 | -- | -34.38 | -- | 18.35 | -- | -864.91 | -- | 0.2009 | -- | 0.0313 | -- | -- | -- | -697.08 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -14.39m | 12.94m | 4.00 | -- | 4.17 | -- | -- | -7.82 | -7.82 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -328.18 | -- | -468.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.45 | -- | -- | -- |
| Cocrystal Pharma Inc | 0.00 | -9.67m | 13.30m | 11.00 | -- | 1.64 | -- | -- | -0.9356 | -0.9356 | 0.00 | 0.5881 | 0.00 | -- | -- | 0.00 | -72.50 | -43.29 | -83.33 | -45.24 | -- | -- | -- | -4,873.78 | -- | -- | 0.00 | -- | -- | -- | 2.67 | -- | -43.98 | -- |
| Check Cap Ltd | 0.00 | -13.62m | 13.41m | 85.00 | -- | 2.86 | -- | -- | -2.33 | -2.33 | 0.00 | 0.6432 | 0.00 | -- | -- | -- | -114.23 | -61.64 | -130.02 | -67.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.15 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -15.31m | 13.59m | 6.00 | -- | 1.13 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 45.20k | 1.93% |
| DRW Securities LLCas of 31 Dec 2025 | 25.15k | 1.08% |
| Citadel Securities LLCas of 30 Sep 2025 | 19.86k | 0.85% |
| Geode Capital Management LLCas of 31 Dec 2025 | 14.53k | 0.62% |
| LPL Financial LLCas of 31 Dec 2025 | 13.00k | 0.56% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 8.71k | 0.37% |
| JPMorgan Securities LLC (Investment Management)as of 31 Dec 2025 | 7.50k | 0.32% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.26k | 0.14% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 1.08k | 0.05% |
| UBS Securities LLCas of 31 Dec 2025 | 1.04k | 0.05% |
